Lilly, Daiichi Explore Pharmacogenomic Marker For Prasugrel
Executive Summary
A May 4 Circulation article describing prasugrel's efficacy in patients who carry a genetic marker indicative of non-response to Plavix may be the opening volley in one of the first big marketing battles of the personalized medicine era
You may also be interested in...
Effient Approval Was Prolonged, But FDA Requirements May Help Sponsors
FDA's approval of Lilly/Daiichi Sankyo's Effient (prasugrel) NDA took longer than either the sponsors or FDA review management liked. Approval took more than a year-and-half to accomplish, with changes occurring to the very last day, July 10
Effient Approval Was Prolonged, But FDA Requirements May Help Sponsors
FDA's approval of Lilly/Daiichi Sankyo's Effient (prasugrel) NDA took longer than either the sponsors or FDA review management liked. Approval took more than a year-and-half to accomplish, with changes occurring to the very last day, July 10
Effient Approval Shows Mark Of FDA Controls
Postmarketing trials offer opportunity to investigate a possible means to control the bleeding caused by prasugrel, but REMS includes messaging aimed at limited off-label use.